HAWK Biosystems 

We increase the outcomes of immune oncology treatments

OWNER

Fernando Aguirre (See Profile)


Sector

Personalised medicine

Stage

Development, market readiness, clinical trial

Country

Spain


We can increase patient's response to immune oncology treatments in solid tumours by a 280%

First technology that truly predicts patient response to immune oncology treatments

Clinically validated in non small cell lung cancer (NSCLC)

Patent granted in all major markets

Multiple other applications in precision medicine, beyond immune oncology

Status

Approved

IP Type

Patent

Time

14 years

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

Method for detecting protein functions in tissue samples

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: 23 November 2022

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

  • AsistensiAllowing migrants to easily purchase the medical he...

©2022 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar